🇺🇸 Leuprolide Acetate for Injectable Suspension in United States

10 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Aspartate Aminotransferase Increased — 1 report (10%)
  2. Asthenia — 1 report (10%)
  3. Blood Calcium Decreased — 1 report (10%)
  4. Blood Glucose Increased — 1 report (10%)
  5. Cellulitis — 1 report (10%)
  6. Cholelithiasis — 1 report (10%)
  7. Electrocardiogram T Wave Inversion — 1 report (10%)
  8. Hypersensitivity — 1 report (10%)
  9. Lymphatic Obstruction — 1 report (10%)
  10. Lymphoedema — 1 report (10%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Leuprolide Acetate for Injectable Suspension approved in United States?

Leuprolide Acetate for Injectable Suspension does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Leuprolide Acetate for Injectable Suspension in United States?

Oakwood Laboratories, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.